Scarica l'app Stockscreener
1.26
4.13%
0.05
Dopo l'orario di chiusura:
1.28
0.02
+1.59%
Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie
CGTX Q1 2026 Earnings: EPS Beat Exceeds Estimates; Cash Runway Supports Alzheimer’s ProgramsShare Repurchase Impact - newsline.com
Cognition Therapeutics (CGTX) Rises 5.26% as Shares Approach Key ResistanceBullish Pattern Stocks - newsline.com
Cognition Therapeutics (CGTX) Gets a Buy from H.C. Wainwright - The Globe and Mail
Cognition Therapeutics (CGTX) Slips 5% as Biotech Momentum FadesIndex Put Call - newsline.com
Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial - TipRanks
Cognition Therapeutics advances zervimesine toward registrational DLB psychosis program; cash into Q2 2027 - TradingView
[8-K] COGNITION THERAPEUTICS INC Reports Material Event - Stock Titan
Cognition Therapeutics Reviews Phase 2 Results With FDA - asatunews.co.id
Cognition Therapeutics Meets FDA and Reduces First Quarter Net Loss - HarianBasis.co
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies? - Insider Monkey
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at June Financial Conferences on DLB Psychosis Registration Program - Quiver Quantitative
Cognition Therapeutics Participating in Upcoming Investor Conferences - The Manila Times
CGTX Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress for Alzheimer’s PipelineFull Year Guidance - newsline.com
Cognition Therapeutics Inc. (CGTX) Q1 2026 Earnings: Narrower‑than‑Expected Loss as Clinical Progress ContinuesPreliminary Results - newsline.com
Cognition Therapeutics (CGTX) Edges Lower as Stock Hovers Near Key SupportPrice Momentum Stocks - The Legal Advocate
CGTX Stock Chart | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
Cognition Therapeutics (CGTX) Holds Steady Near Key Support LevelRatio Spread Trade - newsline.com
CGTX News | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
CGTX Stock Price, Quote & Chart | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
Cognition Therapeutics (CGTX) Slides 1.59% as Biotech Sector Headwinds PersistSentiment Shift - The Legal Advocate
Cognition Therapeutics Inc. (CGTX) Slips Modestly as Stock Hovers Near Support ZoneBPI Bear Confirmed - The Legal Advocate
CGTX Q1 2026 Earnings: Narrower Loss Exceeds Estimates as Pre-Revenue Biotech Advances PipelineFree Cash Flow Trends - Newser
CGTX Q1 2026 Earnings: Cognition Therapeutics Reports Narrower-Than-Expected Loss, No Revenue YetShort-Term Outlook - The Legal Advocate
Cognition Therapeutics Inc. (CGTX) Q1 2026 Earnings: Narrower Loss on Lower Expenses, No Revenue ReportedGuidance Revision Trend - The Legal Advocate
Cognition Therapeutics Advances Zervimesine (CT1812) Toward Registrational Trial for Dementia with Lewy Bodies Psychosis After Positive FDA Meeting - Minichart
Cognition Therapeutics discusses FDA meeting on DLB drug trial By Investing.com - Investing.com South Africa
Cognition Therapeutics discusses FDA meeting on DLB drug trial - Investing.com
Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial - TipRanks
Cognition Therapeutics, Inc. Reports Positive FDA Meeting on Zervimesine Development for Dementia with Lewy Bodies Psychosis - Quiver Quantitative
Cognition Therapeutics completes FDA meeting, sees path for registrational DLB psychosis program - TradingView
Cognition Therapeutics (CGTX) outlines FDA path for zervimesine DLB psychosis trial - Stock Titan
FDA, Cognition discuss next trial for Lewy body dementia psychosis drug - Stock Titan
Cognition Therapeutics Completes Meeting with FDA for - GlobeNewswire
Cognition Therapeutics, Inc.Common Stock (NQ: CGTX - The Chronicle-Journal
CGTX Should I Buy - Intellectia AI
TradingKey - TradingKey
Cognition Therapeutics receives donation to extend DLB program By Investing.com - Investing.com Australia
Cognition Therapeutics receives donation to extend DLB program - Investing.com
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - The Manila Times
Donor extends 2-year access to experimental DLB therapy for 32 people - Stock Titan
Press Release: Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia With Lewy Bodies - Moomoo
H.C. Wainwright Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Chardan Capital Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
COGNITION THERAPEUTICS INC 1Q 2026: Net income $(4.57M), EPS $(0.05) — 10-Q Summary - TradingView
Cognition Therapeutics (NASDAQ: CGTX) Q1 2026 loss narrows on lower R&D - Stock Titan
The fundamentals driving Cognition (CGTX) everyone should understand (Smart Money Outflows) 2026-05-08Volume Dry Up - The Legal Advocate
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update - The Manila Times
Cognition Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cognition Therapeutics (NASDAQ: CGTX) cuts Q1 2026 loss and projects cash runway into Q2 2027 - Stock Titan
Dementia-drug developer gets May 20 FDA meeting as 2027 data loom - Stock Titan
Cognition Therapeutics (NASDAQ: CGTX) CFO has 8,567 shares withheld for taxes - Stock Titan
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):